Skip to content

LAVA Therapeutics NV

CIK 0001840748

← back to feed
Revenue (TTM)
$11.98M
+77.0% YoY Q3 Nov 2025
Net Income (TTM)
−$31.64M
+40.0% YoY Q3 Nov 2025
EPS Diluted (TTM)
−$1.18
+40.1% YoY Q3 Nov 2025
Gross Margin
27.4%
Q3 Nov 2025
Operating Margin
-281.8%
Q3 Nov 2025
Net Margin
-264.0%
Q3 Nov 2025
Free Cash Flow (TTM)
−$19.57M
Q3 Nov 2025
Cash
$49.66M
Q3 Nov 2025
Total Debt
$9.77M
Q3 Nov 2025
Shares Outstanding
26.31M sh
Q3 Nov 2025

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings